{"id":"W4399480809","doi":"10.1200/jco.2024.42.16_suppl.7543","title":"Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Oncology; Internal medicine; Refractory (planetary science)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004538641,0.0009367678,0.001260971,0.0004870449,0.0003660043,0.0007977186,0.0006901615,0.000787872,0.005081093],"category_scores_gemma":[0.003059578,0.0003140317,0.002380943,0.0006456012,0.0005237225,0.0007576744,0.0006951072,0.001779546,0.0004444871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006982896,"about_ca_system_score_gemma":0.0006994595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005758099,"about_ca_topic_score_gemma":0.00137602,"domain_scores_codex":[0.9978124,0.001435257,0.0001485474,0.0002363233,0.0002307751,0.0001367142],"domain_scores_gemma":[0.9974355,0.0007601691,0.00117068,0.0001086371,0.0001186831,0.0004062891],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9127543,0.003769883,0.03980579,0.00107269,0.006209795,0.00006318352,0.00009098827,0.001662793,0.001213119,0.0001928817,0.003476501,0.02968812],"study_design_scores_gemma":[0.5855713,0.1616603,0.2322626,0.0002575965,0.008182781,0.0004359736,0.0002110293,0.003088134,0.002030572,0.0007977188,0.005406038,0.00009594757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979222,0.003400895,0.000558147,0.0003887358,0.00009385453,0.001972567,0.0116775,0.00004888352,0.002637475],"genre_scores_gemma":[0.983721,0.0008337873,0.001012207,0.0005336323,0.00009421581,0.003166668,0.009470335,0.00001283429,0.001155343],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005081093,"threshold_uncertainty_score":0.02400291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07123496320944629,"score_gpt":0.4203326377822693,"score_spread":0.349097674572823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}